Skip to main content
Premium Trial:

Request an Annual Quote

Silence Cancer Drug Advances into Phase IIa Portion of Clinical Study


Silence Therapeutics this week announced that its siRNA-based cancer drug Atu027 has progressed into the phase IIa portion of an ongoing phase Ib/IIa trial.

The drug is a blunt-ended siRNA that is formulated with the company’s proprietary AtuPlex lipid-based delivery technology and targets the protein kinase PKN-3, which is associated with cellular morphology and locomotion in endothelial and cancer cells.

In late May, Silence initiated the phase Ib part of the trial, which is testing Atu027 in combination with the chemotherapeutic gemcitabine in patients with locally advanced or metastatic pancreatic cancer (GSN 5/30/2013).

This week, the company said that the trial’s data safety monitoring board recommended that the phase IIa portion begin after finding that the phase Ib data showed the combination therapy to be well tolerated.

Silence said that it expects to have enrolled all the study’s patients by mid-2014 and complete a one-year follow up by mid-2015.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.